United States: Inventorship, Ownership Issues Cause Dismissal Of Suit

On July 22, 2015, the U.S. District Court for the District of Maryland dismissed a long standing patent infringement suit brought by StemCells, Inc. against Neuralstem, Inc., on the ground that all those with an ownership interest in the patents-in-suit did not voluntarily join as plaintiffs in the action. StemCells, Inc v. Neuralstem, Inc., Case No. 06-cv-187-RWT (D. Md. July 22, 2015). The decision highlights that even informal agreements among collaborators can be construed as assignments of inventions and that there is often a difference of opinion, even among experts, as to who made an inventive contribution to a patent filing.

The Patents-in-Suit and Agreements

The patents-in-suit ("patents") are U.S. Patent Nos.: 5,851,832; 6,497,872; 7,101,709; 7,115,418; and 7,361,505, which are all continuations-in-part of U.S. Serial No.: 07/726,812 (the "'812 application"). The '812 application was filed on July 8, 1991, naming Drs. Samuel Weiss and Brent Reynolds as co-inventors. During the course of examination of the '812 application, inventorship was raised by the USPTO, and in particular, whether Dr. Wolfram Tetzlaff should be named as an inventor of the application. After an investigation by the attorney prosecuting the application, it was determined that Dr. Tetzlaff was not a co-inventor.

On July 3, 1991, just a few days prior to the filing of the '812 application, Drs. Weiss, Reynolds and Tetzlaff signed a memorandum (dated July 2, 1991), agreeing to divide 50% of the ownership among themselves of the potential commercial value of the invention that led to the '812 application (the "1991 Memo"). The remaining 50% ownership interest went to their employer, the University of Calgary, through the university's agent, University Technologies, Inc. ("UTI"). According to the 1991 Memo, the 50% ownership interest due to the self-named inventors was to be allocated as follows: 45% to Dr. Weiss, 45% to Dr. Reynolds, and 10% to Dr. Tetzlaff.

Also on July 3, 1991, Drs. Weiss and Reynolds, but not Dr. Tetzlaff, signed an assignment purporting to assign their interest in the invention of the '812 application to UTI, the commercial out licensing arm of the University of Calgary. Dr. Tetzlaff was not identified as a co-inventor and did not sign the assignment document.

The University of Calgary eventually returned any rights it had in the inventions and patents to Drs. Weiss and Reynolds, who then through a series of transactions eventually assigned them to NeuroSpheres Holdings Ltd. ("NeuroSpheres"). NeuroSpheres executed license agreements with StemCells, which included patent rights in the patent applications (all continuations of the original of the '812 application) that matured into the patents-in-suit. StemCells then asserted them against Neuralstem in this patent infringement action.

A Question of Contribution

Almost 5 years into the lawsuit, defendant Neuralstem filed a motion to dismiss based on the discovery of the 1991 Memo. Neuralstem alleged that should Dr. Tetzlaff have a valid inventorship interest in the patents, then StemCells does not have standing since he never assigned his interested to NeuroSpheres. As a co-owner of the patents, he must join as a party-in-interest. To resolve the issue, the court evaluated whether Dr. Tetzlaff acquired an ownership interest either as a co-inventor of the patents or through the 1991 Memo that may have assigned part ownership of the patents to him.

In first deciding whether Dr. Tetzlaff is a co-inventor, the court evaluated his contributions to the invention.

The court first determined that the invention related to the growth, proliferation and use of neural cells. As stated by the court, Dr. Reynolds came into the possession of the cells that he subsequently put in culture with certain growth factors. He found that unexpectedly, the combination of growth factors not only resulted in more neurons surviving, but also increased cell proliferation.

Several facts were highlighted by the court as being key in the inventorship analysis of the discovery of the growth and proliferation of the cells. It was undisputed that the three scientists knew each other, having worked in close proximity, and that Drs. Weiss and Tetzlaff jointly submitted a 1990 grant application detailing research relating to the discovery. The 1990 grant application acknowledged that Dr. Tetzlaff coordinated all phases of the molecular biology experiments. The court also noted with interest that the three scientists co-authored several technical publications relating to the invention.

In reviewing the testimony from Drs. Weiss, Reynolds and Tetzlaff regarding the contributions of all to the discovery, the court focused on the alleged self-serving testimony of Drs. Weiss and Reynolds in that they characterized Dr. Tetzlaff' s contribution to the invention as financial, and not technical in nature. In contrast, the court noted that Dr. Tetzlaff' s testimony was more convincing and attributed his contribution to the collaboration as two-fold: he did the work necessary to confirm that the discovered neurons would work in animals and he performed the immunocytochemistry to confirm the types of cell that were proliferating. This work was considered by the court to be essential to determine with precision the types of cells that were proliferating. The court also noted that Dr. Tetzlaff designed the human experiments for use of the cells in humans which the court considered to be an essential part of the evolution of the discovery into a patentable invention.

Based on this evidence and the testimony of the three scientists, the court concluded that Dr. Tetzlaff was a co-inventor.

Ownership by Contract

The court then turned to the question of ownership. The agreement among the scientists to share in ownership of the "invention" was evaluated under Canadian contract law. The court stated that the 1991 Memo was confirmatory evidence of a prior oral agreement to share in the ownership interest of the discovery and profits. It was therefore determined to be an effective assignment of any ownership interest in the inventions to each of Drs. Weiss, Reynolds and Tetzlaff. The court also determined that the 1991 Memo was not preempted by the July 3, 1991 assignment to the university because the 1991 Memo was dated and effective one day prior to its signing and the July 3, 1991 assignment to the university.

A Curious Case to Ponder

This case presents a curious situation for at least two reasons. First on the issue of the informal agreements and assignments of inventions, two documents, executed on the same day presented contradictory conclusions as to ownership of the intellectual property. In determining which agreement was controlling, the court heavily relied on the fact that the 1991 Memo was dated and deemed effective one day prior to its signing, and one day prior to the execution of the assignment to the university. As it was first in time (by one day), the 1991 Memo was determined to preempt the university assignment.

Second, on the issue of inventorship, the court did not appear to consider when conception of the invention was complete and more specifically, if Dr. Tetzlaff joined after completed conception by Drs. Reynolds and Weiss, In the federal circuit's decision of Univ. of Pittsburgh v. Hedrick, 91 USPQ2d 1423 (Fed. Cir. 2009), the court held that a scientist, who joined a project after completion of conception of the invention by others and who generated data confirming the prior conception, was not a coinventor. In that case, the Federal Circuit determined that the scientist's whose work simply confirmed the isolation and culturing of a particular type of stem cell was thus was not a co-inventor since such work merely confirmed the conception of others. The court held that it was immaterial that the named inventors did not know with scientific certainty the cells' inventive qualities and that others helped them gain such scientific certainty. Here, while Dr. Tetzlaff assisted with determining clinical use of the cells it is not clear from the court's decision if such was confirmatory of prior conception by Drs. Weiss and Reynolds.

This case has been pending for some time in district court and it is not unlikely that it will continue on appeal, where a review of issues of inventorship, ownership, and standing will continue.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions